Initial Statement of Beneficial Ownership (3)

FORM 3	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^*

Agresta Samuel

2. Date of Event Requiring Statement (MM/DD/YYYY) 10/16/2019

3. Issuer Name and Ticker or Trading Symbol

INFINITY PHARMACEUTICALS, INC. [INFI]

(Last) (First) (Middle)

C/O INFINITY PHARMACEUTICALS, INC., 1100 MASSACHUSETTS AVENUE

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__X__ Director _____ 10% Owner
_____ Officer (give title below) _____ Other (specify below)

(Street)

CAMBRIDGE, MA 02138

(City) (State) (Zip)

5. If Amendment, Date Original Filed(MM/DD/YYYY)

6. Individual or Joint/Group Filing(Check Applicable Line)

_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	10593 ⁽¹⁾	D

*Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)*
1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivate Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security		6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Option (right to buy)	⁽²⁾	⁽⁴⁾	Common Stock	81250	$1.80	D
Stock Option (right to buy)	⁽³⁾	⁽⁴⁾	Common Stock	10433	$1.24	D

Explanation of Responses:
(1)	These 10,593 shares of common stock were acquired by Dr. Agresta on June 14, 2019 during his tenure as the Issuer's Chief Medical Officer and through participation in the issuer's Employee Stock Purchase Plan.
(2)	This option became exercisable as to 12/48th of the 300,000 shares originally subject to the award on August 6, 2019 and as to 1/48th of such shares at the end of each calendar month thereafter until it ceased vesting upon Dr. Agresta's resignation as the Issuer's Chief Medical Officer on September 13, 2019.
(3)	This option became exercisable as to 1/48th of the 62,596 shares originally subject to the award on January 31, 2019 and as to 1/48th of such shares at the end of each calendar month thereafter until it ceased vesting upon Dr. Agresta's resignation as the Issuer's Chief Medical Officer on September 13, 2019.
(4)	Pursuant to a resolution approved by the Issuer's Board of Directors on October 16, 2019, the last date this option may be exercised is the earlier of August 6, 2022, or three months following cessation of Dr. Agresta's service as a member of the Board of Directors.

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Agresta Samuel C/O INFINITY PHARMACEUTICALS, INC. 1100 MASSACHUSETTS AVENUE CAMBRIDGE, MA 02138	X